Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 19, 2006. The report serves as a notification of major interests in the Company's shares, specifically detailing changes in shareholdings by Barclays plc and its subsidiaries in compliance with Part VI of the Companies Act 1985.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification regarding equity ownership and does not contain financial performance data.
Material Changes
The filing details two distinct movements in Barclays plc's total shareholding during May 2006:
- May 12, 2006: Barclays plc's total holding increased from 3.80% to 4.01% of the issued share capital (excluding treasury shares). The aggregate holding across various Barclays entities totaled 233,183,962 shares.
- May 15, 2006: Barclays plc's total holding decreased from 4.01% to 3.73% of the issued share capital. The aggregate holding across the same entities totaled 216,934,923 shares.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for management guidance, future outlook, risk factors, contingencies, or unusual items. The document is strictly limited to reporting statutory shareholding notifications.
Key Facts for Investor Verification
- Barclays plc's ownership stake in GlaxoSmithKline plc fluctuated between 3.73% and 4.01% within a three-day window in mid-May 2006.
- The total number of shares held by Barclays entities dropped by approximately 16.2 million shares between May 12 and May 15, 2006.
- Major holding entities include Barclays Global Investors Ltd, Barclays Global Investors, N.A., and Gerrard Ltd.
- Share capital calculations exclude shares held in Treasury.